Baseline characteristics
| Variable | Dapagliflozin group (n=50) | Control group (n=52) | P value |
| Age (years) | 72.6±12.2 | 74.2±11.3 | 0.48 |
| Male | 29 (58) | 27 (52) | 0.54 |
| De novo acute HF | 17 (34) | 20 (38) | 0.64 |
| Myocardial infarction | 26 (52) | 25 (48) | 0.69 |
| PCI | 14 (28) | 8 (15) | 0.12 |
| CABG | 3 (6) | 2 (4) | 0.68 |
| TD2M | 15 (30) | 16 (30) | 0.93 |
| Arterial hypertension | 46 (92) | 48 (92) | 0.95 |
| Atrial fibrillation | 25 (50) | 30 (57) | 0.44 |
| Pacemaker | 2 (4) | 3 (6) | 0.68 |
| NYHA class IV | 16 (34) | 23 (44) | 0.2 |
| Average eGFR, mL/min | 55.65±18.17 | 52.7±17.34 | 0.62 |
| CKD* | 26 (52) | 31 (59) | 0.43 |
| eGFR less than 45 mL/min | 12 (24) | 14 (27) | 0.7 |
| NT-proBNP at rabdomisation, pg/mL | 5333 (2029.25; 9902.25) | 4381 (2312.5; 11514) | 0.57 |
| Pretreatment time, hours | 17(7.5; 22) | 15(6; 23) | 0.9 |
| Anaemia | 20 (40) | 22 (42) | 0.81 |
| Haemoglobin, g/L | 130.76±21.2 | 124.96±23.9 | 0.2 |
| Blood glucose, mmol/L | 7 (5.38; 8.03) | 6.45 (5.32; 7.68) | 0.59 |
| Troponin, ng/mL | 0.025 (0.02; 0.173) | 0.035 (0.0175; 0.16) | 0.35 |
| Stroke/TIA | 7 (14) | 5 (10) | 0.58 |
| COPD | 16 (32) | 20 (38) | 0.49 |
| Bronchial asthma | 8 (15) | 9 (17) | 0.86 |
| Peptic ulcer disease of the stomach\12-duodenum | 7 (13) | 5 (9) | 0.49 |
| Comorbidity Index | 6.8±2.4 | 7.1±2.2 | 0.4 |
| Pleural effusion | 25 (50) | 35 (67) | 0.07 |
| Oedema | 49 (98) | 50 (96) | 0.6 |
| Anasarka | 1 (2) | 3 (6) | 0.33 |
| SBP at, mm Hg | 132.9±17.9 | 130.1±21.1 | 0.47 |
| DBP at, mm Hg | 78.72±8.7 | 78.5±11 | 0.92 |
| HR (beats/min) | 91.8±17.85 | 93.6±18.92 | 0.6 |
| Medical therapy | |||
| Beta-blocker | 28 (56) | 33 (63) | 0.44 |
| ACEi\ARB | 37 (74) | 35 (67) | 0.46 |
| MRA | 22 (44) | 19 (36) | 0.44 |
| Loop diuretics | 33 (66) | 32 (62) | 0.64 |
| Doses of loop diuretics (in furosemide equivalents), mg | 42.07±11.14 | 46±15.89 | 0.28 |
| ECHO | |||
| LVEF≥50 | 22 (44) | 18 (34) | 0.33 |
| LVEF=41–49 | 7 (14) | 10 (19) | 0.48 |
| LVEF<40 | 21 (42) | 23 (44) | 0.82 |
| Average LVEF | 45.6±15.7 | 44.4±13.6 | 0.62 |
Values are mean±SD, n(%) or median (25th, 75th IQR).
*Estimated glomerular filtration rate (eGFR) less than 60 mL/min.
ACEi/ARB, ACE inhibitors/angiotensin II receptor blockers; CABG, coronary artery bypass graft; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; ECHO, echocardiography; eGFR, estimated glomerular filtration rate; HF, heart failure; HR, heart rate; LVEF, left ventricular ejection fraction; MRA, mineralo-receptor antagonists; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus; TIA, transient ischaemic attack.